Overview

* Aprea Q3 net loss narrows to $3.0 mln from $3.8 mln in prior yr

* Company's cash position expected to support operations into Q4 2026

* Clinical progress in WEE1 and ATR inhibitor programs noted

Outlook

* Aprea plans to explore combination strategies for ATRN-119 with radiation or checkpoint inhibitors

* Company progressing with dose escalation for APR-1051 to 150 mg once daily

* Aprea has cash runway into the fourth quarter of 2026

Result Drivers

* Research and Development (R&D) expenses were $1.6 million for the quarter ended September 30, 2025, compared to $2.8 million for the third quarter of 2024

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.47

Q3 Net -$3 mln

Income

Q3 -$3.10

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy."

* Wall Street's median 12-month price target for Aprea Therapeutics Inc ( APRE ) is $10.50, about 87.4% above its November 11 closing price of $1.32

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)